Glycolysis

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

Retrieved on: 
Thursday, April 11, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, PFS, Patient, Safety, Sepsis, Progression-free survival, Survival, Bevacizumab, Glycolysis, Cohort, OXPHOS, Week, Fatigue, Neoplasm, Trial of the century, Overalls, Abdominal pain, Pharmaceutical industry

This landmark analysis exceeded the 20% threshold set in the Clinical Study Protocol to add an additional 20 patients to the study via the initiation of Cohort 2.

Key Points: 
  • This landmark analysis exceeded the 20% threshold set in the Clinical Study Protocol to add an additional 20 patients to the study via the initiation of Cohort 2.
  • The study was designed to evaluate ME-344 plus bevacizumab in up to two cohorts of approximately 20 patients each.
  • ME-344 in combination with bevacizumab at the dose and schedule evaluated was generally well tolerated with no overlapping toxicities observed.
  • Two patients (9%) discontinued therapy due to an adverse event: fatigue considered related to study drugs and sepsis considered unrelated.

NIMML Institute Presents Pioneering Research on Immunometabolic Mechanisms Related to the Pharmacological Activation of LANCL Receptors at Immunology2024, the Annual Meeting of the American Association of Immunologists

Retrieved on: 
Wednesday, April 10, 2024
Health Technology, Other Health, Technology, Pharmaceutical, Oncology, Mental Health, Philanthropy, Infectious Diseases, Genetics, Artificial Intelligence, Clinical Trials, Foundation, Biotechnology, Science, Research, Health, Eosinophilia, Bronchial hyperresponsiveness, NIMML, Swelling, Choline, PBMC, Gastrointestinal tract, Macrophage, Fibrosis, Red, Atopic dermatitis, Brain, TNF, Inflammation, Phenotype, Abstract, Glycolysis, Lupus, T helper 17 cell, IBD, AAI, Psoriasis, OVA, MASH, Plasma, Fed, Ulcerative colitis, Mouse, COL1A1, Microglia, McCormick Place, Therapy, Carbon tetrachloride, HDM, Immunoglobulin E, IL-6, Medicine, Asthma, House, Neutrophil, Patient, Phagocytosis, Ovalbumin, Rheumatoid arthritis, LANCL2, CDAA, UC

The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.

Key Points: 
  • The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.
  • “We are pleased to present our most recent findings related to the immunometabolic mechanisms of activation of LANCL receptors in inflammation & immunology at this year’s AAI Annual Meeting,” said Dr. Josep Bassaganya-Riera, President and Founding Director of NIMML.
  • NImmune’s portfolio includes first and best-in-class omilancor and NIM-1324, two oral, once-daily agonistic therapeutics that bind and activate the LANCL2 pathway.
  • Title: Pharmacological activation of LANCL2 provides immunometabolic support for the restoration of cognitive function markers in a mouse model of Alzheimer’s disease.

EQS-News: G.ST Antivirals reports start of Phase II trial and announces appointment of Ronald Bruce Turner as new Chief Medical Officer

Retrieved on: 
Wednesday, April 10, 2024
JAMA, Recreational vehicle, Metabolism, CHDR, Entrepreneurship, Dean (education), Viral, Reproduction, University, Head, Volunteering, MD, Urinary tract infection, Infection, Medical school, Clinical trial, Pharmacokinetics, Southern Illinois University, Division, Virus, CMO, University School, Glycolysis, Pharmaceutical industry

An expert in the clinical research of respiratory viruses, Dr. Turner will oversee the Company’s current clinical trial and drive further clinical development.

Key Points: 
  • An expert in the clinical research of respiratory viruses, Dr. Turner will oversee the Company’s current clinical trial and drive further clinical development.
  • This study aims to assess the effectiveness of 2-DG in preventing illness from rhinoviruses, reducing infection rates, and easing symptom severity.
  • A total of 128 volunteers will participate, receiving up to four daily intranasal doses of either 2-DG or a placebo.
  • 2-DG is a unique and intriguing therapeutic approach to treating viral infections by blocking the virus’ nutrient access,” commented Ronald Bruce Turner, MD, CMO of G.ST Antivirals.

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Lung, TUSC2, Agonal respiration, Metabolism, Gene, Apoptosis, Cell, NSCLC, Nanoparticle, Patient, Neoplasm, Research, Pembrolizumab, Date, NPRL2, Lung cancer, Immunity, ATP, ALK, Glycolysis

AUSTIN, Texas, April 9, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid) and NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer. These studies were presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which is being held April 5-10, 2024 in San Diego, California.

Key Points: 
  • Alectinib is an ALK-inhibitor commonly used to treat patients with ALK rearrangements such as EML4-ALK positive NSCLCs.
  • This research suggests that REQORSA may be an effective treatment in patients progressing on alectinib.
  • The study found that the NPRL2 treatment by itself led to a marked decrease in the size of lung metastases but pembrolizumab had no effect.
  • Study findings suggest that NPRL2 gene therapy induces anti-tumor activity against KRAS/STK11mt tumors through dendritic cell-mediated antigen presentation and cytotoxic immune cell activation.

SOTIO Presents New Preclinical Data on Enhanced CAR T-Cell Therapies at AACR Annual Meeting

Retrieved on: 
Tuesday, March 12, 2024
Oncology, Health, Other Health, Other Science, General Health, Research, Science, GOT2, Patient, TIGAR, AACR, Transgene, PPF (company), PARP, Fibroadenoma, Glycolysis, Pharmaceutical industry

SOTIO Biotech , a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, in San Diego, California.

Key Points: 
  • SOTIO Biotech , a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, in San Diego, California.
  • In a poster at the conference, SOTIO will present data from the company’s BOXR platform of enhanced T cell therapies.
  • Compared to unmodified CAR T cells and CAR T cells enhanced with GOT2 solely, CAR T cells enhanced with GOT2 and TIGAR showed better tumor infiltration, lower levels of exhaustion, and superior anti-tumor activity in a mouse model of solid tumors.
  • SOTIO’s lead candidate from the BOXR platform, BOXR1030 — a GOT2-enhanced CAR T-cell therapy — is currently being evaluated in a Phase 1/2 study for patients with solid tumors.

Global Bioplastics and Advanced Plastics Recycling Report 2024-2034: Market Challenges and Opportunities in Scaling Up Environment-friendly Solutions Aligned with Principles of Circular Economy - ResearchAndMarkets.com

Retrieved on: 
Monday, March 4, 2024
Chemicals, Plastics, Recycling, Environment, Manufacturing, Bioplastic, FDCA, Plastics industry, Danimer Scientific, Carbios, Glycolysis, Growth, SWOT, Starch, Biomass, BASF, PHA, Gesellschaft mit beschränkter Haftung, Succinic acid, Lactic acid, Polyethylene, PBS, SABIC, Pyrolysis, OMV, PLA, LyondellBasell, APK, Textile, Plastic, Oil, Agriculture, Market, Versalis, Types of plant oils

The "Global Market for Bioplastics and Advanced (Chemical) Plastics Recycling 2024-2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Market for Bioplastics and Advanced (Chemical) Plastics Recycling 2024-2034" report has been added to ResearchAndMarkets.com's offering.
  • Innovation in bioplastics and plastics recycling is spurring a renaissance in the petrochemical industry, with the latest technologies reinventing plastic and making waste plastic a new resource.
  • The Global Market for Bioplastics and Advanced (Chemical) Plastics Recycling 2024-2034 provides a comprehensive analysis of the global bio-based feedstocks, bio-based plastics, and advanced chemical recycling markets.
  • An extensive section is dedicated to the global bio-based and biodegradable plastics market, segmented by types including PLA, PHA, PBS, bio-PET etc.

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
Glioblastoma, NSCLC, Diabetes, Lung, Lung cancer, Metabolism, EGFR, Osteosarcoma, MD, Neoplasm, FDA, Cancer, Glycolysis, Food, Growth, Anaplastic lymphoma kinase, Pembrolizumab, AACR, Cell, Apoptosis, Date, Osimertinib, Agonal respiration, Mitochondrion, Breast, University, Nanoparticle, Food and Drug Administration, NPRL2, Patient, ATP, Clinical trial, Gene, Disease, TUSC2, Trial of the century, Mesothelioma, Research, ALK, Vaccine

AUSTIN, Texas, March 6, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 in San Diego, California. The collaborators will present positive preclinical data from studies of its lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), as well as NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer.

Key Points: 
  • The collaborators will present positive preclinical data from studies of its lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), as well as NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer.
  • In this humanized mouse model, researchers investigated the anti-tumor immune responses to NPRL2 gene therapy in pembrolizumab resistant KRAS/STK11mt NSCLC.
  • "Today's bolus of compelling data validates the potential of REQORSA and the ONCOPREX Delivery System as innovative cancer treatments.
  • We look forward to continuing to evaluate the ONCOPREX Delivery System using both REQORSA and NPRL2 as potential treatments for lung cancer."

Global Market for Bioplastics and Advanced (Chemical) Plastics Recycling 2024-2034: Detailed Projections on Global Production Capacities for Significant Bio-based Feedstocks up to 2034

Retrieved on: 
Wednesday, February 28, 2024
Bioplastic, FDCA, Plastics industry, Danimer Scientific, Carbios, Glycolysis, Growth, SWOT, Starch, Biomass, BASF, PHA, Gesellschaft mit beschränkter Haftung, Succinic acid, Lactic acid, Polyethylene, PBS, SABIC, Pyrolysis, OMV, PLA, LyondellBasell, APK, Textile, Plastic, Oil, Agriculture, Market, Versalis, Types of plant oils, Recycling

DUBLIN, Feb. 28, 2024 /PRNewswire/ -- The "Global Market for Bioplastics and Advanced (Chemical) Plastics Recycling 2024-2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 28, 2024 /PRNewswire/ -- The "Global Market for Bioplastics and Advanced (Chemical) Plastics Recycling 2024-2034" report has been added to ResearchAndMarkets.com's offering.
  • The Global Market for Bioplastics and Advanced (Chemical) Plastics Recycling 2024-2034 provides a comprehensive analysis of the global bio-based feedstocks, bio-based plastics, and advanced chemical recycling markets.
  • It covers key trends, drivers, latest developments, production capacities, producers, and market segmentation.
  • Market demand projections are provided for chemicals like lactic acid, FDCA, acrylic acid, succinic acid, 1,4-butanediol etc to 2034.

EQS-News: G.ST Antivirals reports positive Phase I trial results for 2-Deoxy-D-glucose against upper respiratory infections

Retrieved on: 
Tuesday, January 30, 2024
Entrepreneurship, Patient, Șaeș, Infection, Drug resistance, CSO, Virus, FFG, Safety, Aes, Urinary tract infection, SAD, Reproduction, Auxiliaries, EUR, Recreational vehicle, Hospital, Glycolysis, Parent, Phase, Metabolism, Pharmacokinetics, Pharmaceutical industry

Results of the Phase I trial demonstrated that an intranasal administration of 2-DG is safe, well tolerated and does not lead to any serious adverse events (SAEs).

Key Points: 
  • Results of the Phase I trial demonstrated that an intranasal administration of 2-DG is safe, well tolerated and does not lead to any serious adverse events (SAEs).
  • Alongside these clinical results, the company has raised funds totalling over EUR 6 million to complete the Phase II clinical trial.
  • “The results of the Phase I trial confirm the safety of our innovative approach of using 2-DG to treat respiratory infections.
  • “While viral infections of the upper respiratory tract are ubiquitous, they are currently insufficiently treated, and RVs are responsible for most of these infections.

MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Bevacizumab, MEI, Glycolysis, Colorectal cancer, Acute myeloid leukemia, Lymphoid leukemia, ASH, Cohort, Investment, Patient, Research, CDK9, Calendar, Wind, VEGF, Exposition, Cancer, AML, Society, Neoplasm, OXPHOS, Venetoclax, Kyowa Kirin, Pharmaceutical industry, Cryptocurrency

The Company anticipates announcing safety and efficacy data from the first cohort of 20 patients in the first half of 2024.

Key Points: 
  • The Company anticipates announcing safety and efficacy data from the first cohort of 20 patients in the first half of 2024.
  • For the quarter ended September 30, 2023, cash used in operations was $18.5 million, compared to $14.8 million during the quarter ended September 30, 2022.
  • Research and development expenses were $3.5 million for the quarter ended September 30, 2023, compared to $19.5 million for the quarter ended September 30, 2022.
  • MEI recognized revenue of $65.3 million for the quarter ended September 30, 2023, compared to $8.7 million for the quarter ended September 30, 2022.